Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up

Glaxosmithkline Share Price (GSK)

Show Chart Filters
Time period:
Moving Average:
Compare to:
Price 1,582.00on 24-05-2019 at 16:30:00
Change 10.40 0.66%
Buy 1,581.60
Sell 1,581.20
Buy / Sell GSK Shares
Sponsored Financial Content
Last Trade: Buy 76,133 at 1,582.00p
Day's Volume: 5,548,070
Last Close: 1,571.60p
Open: 1,577.60p
ISIN: GB0009252882
Day's Range 1,570.60p - 1,586.80p
52wk Range: 1,408.80p - 1,648.80p
Market Capitalisation: £78,246m
VWAP: 0.00p
Shares in Issue: 4,946m

Recent Trades History Glaxosmithkline (GSK)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy*76,1331,582.0017:11:59 - 24-May-19
Sell*2171,572.35718:28:17 - 24-May-19
Sell*524,9721,579.52317:44:40 - 24-May-19
Sell*1111,579.43817:16:05 - 24-May-19
Sell*8141,572.43417:10:48 - 24-May-19
Sell*321,572.35617:10:04 - 24-May-19
Buy*5891,581.90217:06:32 - 24-May-19
Buy*47,1151,581.84017:06:32 - 24-May-19
Buy*1,1961,581.9117:06:32 - 24-May-19
Buy*6,4231,581.89017:06:32 - 24-May-19

Share Price History for Glaxosmithkline

Time period:
Date Open High Low Close Volume
24th May 2019 (Fri)1,577.601,586.801,570.601,571.605,548,070
23rd May 2019 (Thu)1,580.601,594.801,571.401,571.207,779,363
22nd May 2019 (Wed)1,547.001,571.201,543.401,544.6011,438,188
21st May 2019 (Tue)1,551.801,558.601,539.200.005,887,779
20th May 2019 (Mon)1,554.001,557.001,538.401,555.004,157,633
17th May 2019 (Fri)1,544.001,557.801,536.801,550.0020,150,479
16th May 2019 (Thu)1,525.801,550.001,517.201,534.006,042,109
15th May 2019 (Wed)1,520.601,539.001,518.201,516.607,235,156
14th May 2019 (Tue)1,519.201,527.401,513.601,512.404,482,478
13th May 2019 (Mon)1,508.601,513.801,495.401,502.005,598,127
10th May 2019 (Fri)1,520.801,527.601,498.001,518.205,536,677
9th May 2019 (Thu)1,520.001,531.201,511.601,524.405,786,903
8th May 2019 (Wed)1,515.001,532.801,506.801,517.805,790,681
7th May 2019 (Tue)1,545.001,551.401,514.201,552.2010,924,240
6th May 2019 (Mon)
3rd May 2019 (Fri)1,555.201,572.001,545.801,547.405,834,203
2nd May 2019 (Thu)1,585.001,585.001,545.801,559.806,520,441
1st May 2019 (Wed)1,575.201,598.001,532.001,573.4011,132,618
30th Apr 2019 (Tue)1,569.001,582.601,557.401,569.207,003,022
29th Apr 2019 (Mon)1,567.201,573.201,554.201,561.404,764,105
26th Apr 2019 (Fri)1,563.801,569.001,552.401,555.207,831,873

GSK - Glaxosmithkline Investor Summary

GlaxoSmithKline, or 'GSK', is one of the world's leading pharmaceutical companies researching medicines and vacines alike for the World Health Organization's three priority diseases: HIV/AIDS, Malaria and Tuberculosis. With an estimated 7% of the world's pharmaceutical market under its wing, GSK remains one of the industry leaders globally but remains committed to the research and application of life changing and marketable drugs.

If investing in science seems a little confusing and unpredictable then perhaps some of GSK's over-the-counter and more recognisable products will help to convince; these include Gaviscon and Panadol, smoking control products such as Nicorette/Niquitin and nutritional healthcare drinks such as Lucozade, Ribena and Horlicks.

On 23rd January 2009, GSK announced that it had signed an agreement with UCB S.A to acquire its marketed product portfolio in certain parts of the Middle East, Africa, Latin America and Asia Pacific, for a cash consideration of some £484 million. President of Emerging Markets at GSK, Abbas Hussain, said that "This acquisition will strengthen and expand GSK's product portfolio in these countries, helping us to meet the needs of patients, particularly in the areas of epilepsy and respiratory." Under the agreement, GSK acquires several leading pharmaceutical brands and investors will be interested to know that the commercial operations and product distribution rights included represent approximately 3-4% of UCB's 2008 expected revenue of at least £3.09 billion. At the time of Mr Hussain speaking, share prices for GSK were steady at 1,226.00p with a "strong buy" recommendation from brokers.

News about Glaxosmithkline (GSK)

GlaxoSmithKline Admits Employees Broke The Law In China

News - Sunday, May 26, 2019

The head of emerging markets at GlaxoSmithKline, Abbas Hussain, has issued a statement admitting that employees had acted in breach of Chinese Law and stating that the company will review the way it operated in China, amidst a corruption and bribery scandal....

Pharmaceuticals Deals Boost FTSE

News - Sunday, May 26, 2019

The FTSE 100 closed up by 56.51 points, or 0.9 percent, on Tuesday, thanks to some positive activity in the pharmaceuticals sector. By the end of the trading session on Tuesday the FTSE 100 was up to 6,681.76, sitting at a two week high, and close to its closing peak for the year....

FTSE 100 Latest

Login to your account

Forgot Password?

Not Registered